Objective To investigate the changes in the senescence-and function-related parameters of CD8+T cells after direct-acting antiviral( DAA) treatment and their clinical significance in patients with hepatitis C virus( HCV) infection. Methods A total of 26 patients with HCV infection who attended the Second Affiliated Hospital of Air Force Medical University from January 2017 to December 2018 were enrolled,and all patients were given sofosbuvir and daclatasvir tablets. A total of 22 patients who were cured and 20 healthy controls were enrolled. Flow cytometry was used to measure the expression of silent information regulator 1( SIRT1),CD57,programmed death-1( PD-1),and Tim-3 on CD8+T cells; RT-PCR was used to measure the expression of p21 and p53; Luminex liquid suspension chip was used to observe senescence-associated secretory phenotype in peripheral blood. A one-way analysis of variance was used for comparison of continuous data between multiple groups,and the least significant difference t-test was used for further comparison between two groups. Results There were significant differences in the expression of SIRT1,PD-1,and Tim-3 between the three groups( F = 6. 712,4. 202,and 4. 575,all P < 0. 05). Compared with the healthy control group,the HCV group had significant increases in the expression of SIRT1,PD-1,and Tim-3 on CD8+T cells( all P < 0. 05),and the HCV cured group had a significant increase in the expression of Tim-3( P< 0. 05),with no significant changes in SIRT1 and PD-1( both P > 0. 05). There were significant differences in the expression of p53 and p21 between the three groups( F = 11. 144 and 6. 594,both P < 0. 05). Compared with the healthy control group,the HCV cured group and the HCV group had significant reductions in the expression of p53( both P < 0. 001) and p21( both P < 0. 05),and there were no significant differences between the HCV group and the HCV cured group( both P > 0. 05). There were significant differences in interleukin-6 ( IL-6) and tumor necrosis factor α( TNFα) between the three groups( F = 3. 920 and 6. 337,both P < 0. 05),and compared with the healthy control group,the HCV group had significant increases in the levels of IL-6 and TNFα in peripheral blood( both P < 0. 05). There were no significant changes in IL-6 and TNFα in the HCV cured group( both P > 0. 05),and compared with the HCV group,the HCV cured group had a significant reduction in the level of TNFα( P = 0. 007). Conclusion Senescence of CD8+T cells is observed in patients with HCV infection and is alleviated after DAA treatment,with partial recovery of the function of CD8+T cells.
[1]ZHOU Y,LI GY,REN JP,et al.Protection of CD4+T cells from hepatitis C virus infection-associated senescence viaΔNp63-miR-181a-Sirt1 pathway[J].J Leukoc Biol,2016,100(5):1201-1211.
|
[2]SHI JJ,WANG FS.The mechanisms of virus-specific CD8+T-cell dysfunction in HCV infection[J].J Immunol,2015,31(5):446-449.(in Chinese)史继静,王福生.HCV感染导致特异性CD8+T细胞功能障碍机制的研究进展[J].免疫学杂志,2015,31(5):446-449.
|
[3]European Association for the Study of the Liver.EASL recommendations on treatment of hepatitis C 2016[J].J Hepatol,2017,66:153-194.
|
[4]VRANJKOVIC A,DEONARINE F,KAKA S,et al.Direct-acting antiviral treatment of HCV infection does not resolve the dysfunction of circulating CD8+T-cells in advanced liver disease[J].Front Immunol,2019,10:1926.
|
[5]QIAN Y,CHEN X.Senescence regulation by the p53 protein family[J].Methods Mol Biol,2013,965:37-61.
|
[6]BORGDORFF V,LLEONART ME,BISHOP CL,et al.Multiple microRNAs rescue from Ras-induced senescence by inhibiting p21(Waf1/Cip1)[J].Oncogene,2010,29(15):2262-2271.
|
[7]HOARE M,GELSON WT,DAS A,et al.CD4+T-lymphocyte telomere length is related to fibrosis stage,clinical outcome and treatment response in chronic hepatitis C virus infection[J].J Hepatol,2010,53(2):252-260.
|
[8]WANDRER F,HAN B,LIEBIG S,et al.Senescence mirrors the extent of liver fibrosis in chronic hepatitis C virus infection[J].Aliment Pharmacol Ther,2018,48(3):270-280.
|
[9]BARATHAN M,MOHAMED R,SAEIDI A,et al.Increased frequency of late-senescent T cells lacking CD127 in chronic hepatitis C disease[J].Eur J Clin Invest,2015,45(5):466-474.
|
[10]AKBAR AN,HENSON SM,LANNA A.Senescence of T lymphocytes:Implications for enhancing human immunity[J].Trends Immunol,2016,37(12):866-876.
|
[11]AREGAY A,OWUSU SEKYERE S,DETERDING K,et al.Elimination of hepatitis C virus has limited impact on the functional and mitochondrial impairment of HCV-specific CD8+T cell responses[J].J Hepatol,2019,71(5):889-899.
|
[12]BARATHAN M,MOHAMED R,VADIVELU J,et al.CD8+T cells of chronic HCV-infected patients express multiple negative immune checkpoints following stimulation with HCV peptides[J].Cell Immunol,2017,313:1-9.
|
[13]GAO Y,LIANG ZJ,FU J.Influence of sofosbuvir-based antiviral therapy on the expression profile of cytokines and chemokines in patients with chronic hepatitis C[J].J Clin Hepatol,2019,35(10):2200-2204.(in Chinese)高艺,梁志军,符健.以索磷布韦为基础的治疗方案对慢性丙型肝炎患者细胞因子/趋化因子表达谱的影响[J].临床肝胆病杂志,2019,35(10):2200-2204.
|
[14]NASEEM S,MANZOOR S,JAVED A,et al.Interleukin-6 rescues lymphocyte from apoptosis and exhaustion induced by chronic hepatitis C virus infection[J].Viral Immunol,2018,31(9):624-631.
|
[15]ROMANI S,STAFFORD K,NELSON A,et al.Peripheral PD-1+Tcells co-expressing inhibitory receptors predict SVR with ultra short duration DAA therapy in HCV infection[J].Front Immunol,2019,10:1470.
|